AI Article Synopsis
- * Reduced uptake of I-BMIPP can indicate issues related to heart conditions, especially in patients with coronary artery disease (CAD).
- * While I-BMIPP is widely used in Japan due to its practical benefits, such as no need for stress tests, its use is limited elsewhere due to regulatory hurdles and supply issues, highlighting the need for broader adoption internationally.
Article Abstract
I-BMIPP (Iodine-123 labeled beta-methyl-p-iodophenyl-pentadecanoic acid) is a radiotracer that facilitates non-invasive assessment of myocardial fatty acid metabolism through single photon emission computed tomography imaging. Given that fatty acids serve as one of the primary energy sources for cardiac muscle, reduced uptake of I-BMIPP offers valuable insights into the pathophysiology of various cardiac conditions, particularly in coronary artery disease (CAD). Despite its reported efficacy, the use of I-BMIPP remains limited outside Japan, primarily due to regulatory and supply challenges. However, in Japan, I-BMIPP is clinically utilized for CAD patients with various ischemic conditions as the protocol does not require stress tests or contrast iodine and has a relatively short acquisition time. This review highlights the clinical applications of I-BMIPP across various conditions and aims to promote its broader adoption in clinical practice, both in Japan and internationally.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11612396 | PMC |
| http://dx.doi.org/10.17996/anc.24-00006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Carnitine Administration and I-BMIPP Washout Rate in Hemodialysis Patients with Triglyceride Deposit Cardiomyovasculopathy.
Ann Nucl Cardiol
October 2024
Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Japan.
Triglyceride deposit cardiomyovasculopathy (TGCV) is an emerging rare heart disease with high mortality, characterized by defective intracellular lipolysis of triglycerides (TG). We developed diagnostic criteria for TGCV, in which low washout rate of BMIPP (BMIPP-WR) is a key factor. The working group of the Japan Society of Nuclear Cardiology recently published practice recommendations for measuring BMIPP-WR.
View Article and Find Full Text PDFUnderrecognized Utility of I-BMIPP in CAD Diagnosis Outside of Japan.
Ann Nucl Cardiol
October 2024
Department of Radiology, Sakakibara Heart Institute, Tokyo, Japan.
Article Synopsis
- * Reduced uptake of I-BMIPP can indicate issues related to heart conditions, especially in patients with coronary artery disease (CAD).
- * While I-BMIPP is widely used in Japan due to its practical benefits, such as no need for stress tests, its use is limited elsewhere due to regulatory hurdles and supply issues, highlighting the need for broader adoption internationally.
Potential Application of the Myocardial Scintigraphy Agent [I]BMIPP in Colon Cancer Cell Imaging.
Int J Mol Sci
July 2024
Faculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Japan.
[I]β-methyl-p-iodophenyl-pentadecanoic acid ([I]BMIPP), which is used for nuclear medicine imaging of myocardial fatty acid metabolism, accumulates in cancer cells. However, the mechanism of accumulation remains unknown. Therefore, this study aimed to elucidate the accumulation and accumulation mechanism of [I]BMIPP in cancer cells.
View Article and Find Full Text PDFSPECT Imaging of Infection in Mice Using I-BMIPP.
Pharmaceutics
May 2024
Faculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Japan.
infection is an infectious disease that must be controlled because it becomes chronic and difficult to treat, owing to its unique system of toxin production/injection and elimination of other bacteria. Here, we noninvasively monitored using single-photon emission computed tomography (SPECT) imaging. Determining the amount and localization of the will enable making faster clinical diagnoses and selecting the most appropriate therapeutic agents and methods.
View Article and Find Full Text PDFComparison of Echocardiography and Myocardial Scintigraphy to Detect Cancer Therapy-Related Cardiovascular Toxicity in Breast Cancer Patients.
J Imaging
February 2024
Department of Radiology, Kawasaki Municipal Ida Hospital, Kawasaki 211-0035, Japan.
Article Synopsis
- The mortality rate for cancer patients is declining, but many experience heart issues linked to cancer treatments, prompting increased interest in cardio-oncology.
- The European Society of Cardiology's recent guidelines address these concerns, highlighting the challenges breast cancer patients face with echocardiography due to physical limitations.
- A study comparing myocardial scintigraphy with echocardiography in 114 breast cancer patients found no significant correlation between the two diagnostic methods, indicating that scintigraphy may not effectively replace echocardiography in these cases.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!